Deals In Depth: November 2012
Executive Summary
Forest received US rights to Adamas’ Phase III Alzheimer’s candidate. Reckitt beat out Bayer in a competing $1.4 billion bid for Schiff Nutrition. Biopharma companies raised $1.1 billion in November, while device funding totaled $211 million.